GE Aerospace stock pops in first 2026 session — here’s what Wall Street is watching next
2 January 2026
1 min read

GE Aerospace stock pops in first 2026 session — here’s what Wall Street is watching next

NEW YORK, January 2, 2026, 12:53 ET — Regular session

GE Aerospace (NYSE:GE) shares rose 2.1% to $314.62 in midday trading on Friday, kicking off 2026 on a firmer note after touching an intraday high of $316.80. The stock opened at $309.75, and volume was about 1.7 million shares.

The early move matters because GE has become a bellwether for aerospace demand and maintenance spending, both closely tied to airline flying activity and aircraft deliveries. With a new year starting, investors are resetting portfolios while looking for evidence that last year’s winners can keep delivering.

Traders are also bracing for a fast run of market-moving data, starting with the Jan. 9 U.S. jobs report and Jan. 13 inflation numbers that could reshape expectations for the Federal Reserve’s next rate decision, Reuters reported. “The market is looking for direction,” said Matthew Maley, chief market strategist at Miller Tabak. 1

GE’s advance came alongside gains in other aerospace-linked names. Boeing rose 3.2%, RTX added 0.7% and Howmet Aerospace gained 1.4%.

Broader U.S. equities opened 2026 higher, with technology stocks leading a rebound after a choppy finish to 2025, Reuters reported. That tone helped lift cyclical pockets of the market, including industrials and defense-related shares. 2

GE Aerospace makes and services jet engines and related systems, and it earns a large share of profit from the “aftermarket” — maintenance and repairs airlines buy after engines are delivered.

The next company catalyst is close. GE’s investor calendar lists its fourth-quarter 2025 earnings webcast for Jan. 22. 3

Investors will be listening for any changes in expectations around engine deliveries, services growth and free cash flow — the cash left after capital spending — as airlines and plane makers push to raise output.

GE also has a 36-cent quarterly dividend due to be paid on Jan. 26, the company said, with the record and ex-dividend dates set for Dec. 29. 4

The stock is coming off a big year. GE shares surged nearly 84% in 2025, Investors’ Business Daily reported, leaving less room for disappointment as the earnings season approaches. 5

With the stock near session highs, traders will be watching whether GE can hold its early gains into the afternoon as volume builds after the holiday period. A firm close near the day’s high would keep momentum on the bulls’ side.

For now, GE’s early-year strength keeps the spotlight on aerospace as investors weigh the next round of economic data and prepare for a January earnings rush.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
IREN stock jumps 11% as bitcoin nears $90,000; SEC filing adds dilution watch
Previous Story

IREN stock jumps 11% as bitcoin nears $90,000; SEC filing adds dilution watch

Fluence Energy stock jumps nearly 16% today as rate bets shift — what’s driving FLNC
Next Story

Fluence Energy stock jumps nearly 16% today as rate bets shift — what’s driving FLNC

Go toTop